Fractyl Health (NASDAQ:GUTS) Stock Gets Price Target Trim from Morgan Stanley

Fractyl Health (NASDAQ:GUTS) had its price target decreased by Morgan Stanley to $4.00 in a research note issued to investors on Monday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

Several other analysts also recently commented on the stock. Weiss Ratings downgraded shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Craig Hallum set a $5.00 price target on shares of Fractyl Health in a report on Monday. Finally, Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Fractyl Health has a consensus rating of “Hold” and an average price target of $50.25.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS opened at $1.15 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. Fractyl Health has a 12-month low of $1.11 and a 12-month high of $29.34. The business’s 50 day moving average is $6.47 and its 200 day moving average is $7.97.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. As a group, equities analysts predict that Fractyl Health will post -5.88 EPS for the current fiscal year.

Institutional Trading of Fractyl Health

A number of large investors have recently added to or reduced their stakes in GUTS. Sanctuary Advisors LLC bought a new position in shares of Fractyl Health during the 2nd quarter valued at approximately $26,000. FNY Investment Advisers LLC increased its stake in shares of Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after purchasing an additional 29,920 shares during the last quarter. Accredited Investors Inc. purchased a new stake in shares of Fractyl Health during the 1st quarter worth approximately $46,000. PEAK6 LLC bought a new stake in shares of Fractyl Health in the 2nd quarter worth approximately $159,000. Finally, BlackRock Inc. bought a new stake in shares of Fractyl Health in the 2nd quarter worth approximately $1,431,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.